In a recent Law360 piece, Adam analyzes the reconsidered ruling in Giant Eagle v. American Guarantee, et al., which provides assurance to excess carriers that opioid defendants facing millions of dollars in defense costs cannot use those costs as a means to leapfrog their primary coverage and proceed up their insurance towers to reach excess layers.

BatesCarey is pleased to announce that Paige Houin will present "Opioids, COVID-19, and Beyond: How to Abate the Nuisance Driving Social Inflation" at the 2021 CLM Annual Conference in Atlanta from June 6-18, 2021.

BatesCarey COVID-19 team members Adam H. Fleischer and Matthew P. Fortin summarize recent cases dismissing COVID-19 business interruption claims.

In a recent Law360 piece, Adam unpacks the hierarchy of opioid coverage issues and the recent rulings at the heart of the confusion.

BatesCarey is pleased to announce that Kevin Harris will present “The Opioid Epidemic and Insurance” at the 2020 Casualty Actuarial Society’s “Virtual Annual Meeting.”

In the most recent update from the BatesCarey COVID-19 team, Adam H. Fleischer and Matthew P. Fortin summarize recent rulings which expose flaws in COVID-19 business interruption claims.

Kristi S. Nolley and Lindsey D. Dean discuss the impact of two recent construction defect coverage decisions.

COVID-19 business interruption lawsuits have sought class certification for quick and one-size-fits-all coverage rulings.

Opioid bellwether lawsuits are asserting claims for public nuisance and conspiracy that push the bounds of tort liability. R. Patrick Bedell and Allyson C. Spacht evaluate whether liability insurance applies to these novel claims.

BatesCarey examines expected third-party liability COVID-19 claims and how these claims might be treated under pollution provisions in liability coverage.